Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1218.64.10016 Boehringer Ingelheim Investigational Site
mi
from
Decatur, GA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1218.64.10016 Boehringer Ingelheim Investigational Site
mi
from
Decatur, GA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10128 Boehringer Ingelheim Investigational Site
mi
from
Avon, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10128 Boehringer Ingelheim Investigational Site
mi
from
Avon, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
205.452.01301 Boehringer Ingelheim Investigational Site
mi
from
Fishers, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
205.452.01301 Boehringer Ingelheim Investigational Site
mi
from
Fishers, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1199.14.1152 Boehringer Ingelheim Investigational Site
mi
from
Indianapolis, IN
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.23.10117 Boehringer Ingelheim Investigational Site
mi
from
Arkansas City, KA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.23.10117 Boehringer Ingelheim Investigational Site
mi
from
Arkansas City, KA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1199.14.1097 Boehringer Ingelheim Investigational Site
mi
from
Wichita, KA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1199.14.1097 Boehringer Ingelheim Investigational Site
mi
from
Wichita, KA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1199.14.1172 Boehringer Ingelheim Investigational Site
mi
from
Louisville, KY
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.25.10051 Boehringer Ingelheim Investigational Site
mi
from
Watertown, MA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.25.10051 Boehringer Ingelheim Investigational Site
mi
from
Watertown, MA
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10115 Boehringer Ingelheim Investigational Site
mi
from
Brick, NJ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10115 Boehringer Ingelheim Investigational Site
mi
from
Brick, NJ
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10129 Boehringer Ingelheim Investigational Site
mi
from
Carlisle, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10129 Boehringer Ingelheim Investigational Site
mi
from
Carlisle, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Cincinnati, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.20.10130 Boehringer Ingelheim Investigational Site
mi
from
Gallipolis, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.20.10130 Boehringer Ingelheim Investigational Site
mi
from
Gallipolis, OH
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
1245.23.10153 Boehringer Ingelheim Investigational Site
mi
from
Hurst, TX
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
1245.23.10153 Boehringer Ingelheim Investigational Site
mi
from
Hurst, TX
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Phase III, 24 wk, Efficacy of BI 10773 vs. Placebo and Sitagliptin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Effectiveness and Safety Study of the DexComâ„¢ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
Effectiveness and Safety Study of the DexComâ„¢ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
Status: Archived
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Effectiveness and Safety Study of the DexComâ„¢ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
Effectiveness and Safety Study of the DexComâ„¢ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Vitamin D for Improving Metabolic Control and Depressive Symptoms
Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study
Status: Archived
Loyola University Medical Center
mi
from
Proviso, IL
Vitamin D for Improving Metabolic Control and Depressive Symptoms
Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
mi
from
Proviso, IL
Understanding of Genetic Risk Information for Type 2 Diabetes
Implications of Health and Genetic Literacy for Genomic Medicine
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Understanding of Genetic Risk Information for Type 2 Diabetes
Implications of Health and Genetic Literacy for Genomic Medicine
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Ehealth: Second Life Impacts Diabetes Education & Self-Management
Ehealth: Second Life Impacts Diabetes Education & Self-Management
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Ehealth: Second Life Impacts Diabetes Education & Self-Management
Ehealth: Second Life Impacts Diabetes Education & Self-Management
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Center for Fertility and Women's Health
mi
from
New Britain, CT
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Center for Fertility and Women's Health
mi
from
New Britain, CT
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Abington Memorial Hospital
mi
from
Abington, PA
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Abington Memorial Hospital
mi
from
Abington, PA
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Lexington, KY
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lexington, KY
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Abington, PA
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Abington, PA
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Columbia, SC
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Columbia, SC
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus (0431-251)
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Hazard, KY
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hazard, KY
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Boston, MA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Minneapolis, MN
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Minneapolis, MN
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Nashua, NH
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Nashua, NH
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Children`s Hospital of Philadelphia : University of Philadelphia
mi
from
Philadelphia, PA
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Clinical Research Facility
mi
from
Portland, OR
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Portland, OR